GlobeNewswire Inc.··NaAllarity Therapeutics Secures $20M Funding to Accelerate Stenoparib FDA Path
Allarity Therapeutics secures $20M non-dilutive debt financing to complete stenoparib Phase 2 trial and advance toward FDA approval, extending runway to mid-2028.
ALLRFDA approvaldebt financing